//www.ayxapp78.com/ 2018-12-04 每月 1．0 //www.ayxapp78.com/news-and-press/company-statements/kite-pharma 2018-12-04 每月 0.9 //www.ayxapp78.com/news-and-press/company-statements/100-corporate-equality-score 2018-12-04 每月 0.9 //www.ayxapp78.com/purpose/giving/gilead-foundation 2018-12-04 每月 0.9 //www.ayxapp78.com/purpose/medication-access/us-patient-access 2018-12-04 每月 0.9 //www.ayxapp78.com/utility/global-operations/europe/poland 2018-12-04 每月 0.9 //www.ayxapp78.com/purpose/giving 2018-12-04 每月 0.9 //www.ayxapp78.com/about/ethics-and-code-of-conduct/authorized-distributors 2018-12-04 每月 0.9 //www.ayxapp78.com/utility/global-operations/europe/switzerland 2018-12-04 每月 0.9 //www.ayxapp78.com/news-and-press/company-statements/gilead-supports-prep-education 2018-12-04 每月 0.9 //www.ayxapp78.com/sitemap 2018-12-04 每月 0.9 //www.ayxapp78.com/about/ethics-and-code-of-conduct/supplier-info 2018-12-04 每月 0.9 //www.ayxapp78.com/science-and-medicine/medicines 2018-12-04 每月 0.9 //www.ayxapp78.com/news-and-press/company-statements 2018-12-04 每月 0.9 //www.ayxapp78.com/utility/global-operations/europe/turkey 2018-12-04 每月 0.9 //www.ayxapp78.com/news-and-press/company-statements/top-corporate-philanthropist 2018-12-04 每月 0.9 //www.ayxapp78.com/utility/global-operations/europe/finland 2018-12-04 每月 0.9 //www.ayxapp78.com/purpose/medication-access 2018-12-04 每月 0.9 //www.ayxapp78.com/About/Ethics-and-Code-of-Conduct/Policies 2018-12-04 每月 0.9 //www.ayxapp78.com/About/Ethics-and-Code-of-Conduct/Global-Transparency 2018-12-04 每月 0.9 //www.ayxapp78.com/utility/global-operations/europe/germany 2018-12-04 每月 0.9 //www.ayxapp78.com/purpose/advancing-global-health 2018-12-04 每月 0.9 //www.ayxapp78.com/utility/global-operations/south-america/argentina 2018-12-04 每月 0.9 //www.ayxapp78.com/utility/global-operations/europe/spain 2018-12-04 每月 0.9 //www.ayxapp78.com/privacy-statements/cookie-statement 2018-12-04 每月 0.9 //www.ayxapp78.com/utility/global-operations/africa/south-africa 2018-12-04 每月 0.9 //www.ayxapp78.com/news-and-press/company-statements/authorized-generics-for-hcv 2018-12-04 每月 0.9 //www.ayxapp78.com/utility/global-operations/europe/greece 2018-12-04 每月 0.9 //www.ayxapp78.com/news-and-press/annual-report/year-in-review-2017 2018-12-04 每月 0.9 //www.ayxapp78.com/utility/global-operations/asia/korea 2018-12-04 每月 0.9 //www.ayxapp78.com/purpose/advancing-global-health/hcv-elimination 2018-12-04 每月 0.9 //www.ayxapp78.com/utility/global-operations/asia/japan 2018-12-04 每月 0.9 //www.ayxapp78.com/utility/contact/request-medication-information 2018-12-04 每月 0.9 //www.ayxapp78.com/science-and-medicine/pipeline 2018-12-04 每月 0.9 //www.ayxapp78.com/news-and-press/press-room/press-releases 2018-12-04 每月 0.9 //www.ayxapp78.com/social-media-guidelines 2018-12-04 每月 0.9 //www.ayxapp78.com/purpose/giving/grant-recipients 2018-12-04 每月 0.9 //www.ayxapp78.com/purpose/giving/gilead-public-health-award 2018-12-04 每月 0.9 //www.ayxapp78.com/utility/global-operations/asia/china 2018-12-04 每月 0.9 //www.ayxapp78.com/news-and-press/annual-report 2018-12-04 每月 0.9 //www.ayxapp78.com/news-and-press/company-statements/corporate-contributions-report 2018-12-04 每月 0.9 //www.ayxapp78.com/news-and-press/company-statements/discover-study-of-ftaf-for-prep 2018-12-04 每月 0.9 //www.ayxapp78.com/utility/global-operations/europe/belgium-luxembourg 2018-12-04 每月 0.9 //www.ayxapp78.com/news-and-press/press-room/press-releases/2018/11/china-national-medical-products-administration-nmpa-approves-gileads-vemlidy-tenofovir-alafenamide-for-chronic-hepatitis-b-virus-hbv-infection 2018-12-04 每月 0.9 //www.ayxapp78.com/ayx北京赛车careers/diversity-and-inclusion 2018-12-04 每月 0.9 //www.ayxapp78.com/utility/global-operations/europe/russia 2018-12-04 每月 0.9 //www.ayxapp78.com/science-and-medicine/research/hiv-hcv-no-co-infection-2018 2018-12-04 每月 0.9 //www.ayxapp78.com/social-media-guidelines/linkedin-guidelines 2018-12-04 每月 0.9 //www.ayxapp78.com/about/us-locations 2018-12-04 每月 0.9 //www.ayxapp78.com/news-and-press/press-room/press-faqs 2018-12-04 每月 0.9 //www.ayxapp78.com/social-media-guidelines/twitter-guidelines 2018-12-04 每月 0.9 //www.ayxapp78.com/utility/contact/partnership-request 2018-12-04 每月 0.9 //www.ayxapp78.com/news-and-press/company-statements/hiv-medicines-reach-10-million-people 2018-12-04 每月 0.9 //www.ayxapp78.com/science-and-medicine/research 2018-12-04 每月 0.9 //www.ayxapp78.com/utility/global-operations/asia/hong-kong 2018-12-04 每月 0.9 //www.ayxapp78.com/utility/global-operations/europe/israel 2018-12-04 每月 0.9 //www.ayxapp78.com/about/leadership 2018-12-04 每月 0.9 //www.ayxapp78.com/utility/global-operations/europe/italy 2018-12-04 每月 0.9 //www.ayxapp78.com/purpose/advancing-global-health/ebola 2018-12-04 每月 0.9 //www.ayxapp78.com/utility/global-operations/australia/australia-new-zealand 2018-12-04 每月 0.9 //www.ayxapp78.com/utility/global-operations/europe/norway 2018-12-04 每月 0.9 //www.ayxapp78.com/purpose/partnerships-and-community/gilead-lift 2018-12-04 每月 0.9 //www.ayxapp78.com/purpose/partnerships-and-community 2018-12-04 每月 0.9 //www.ayxapp78.com/purpose/partnerships-and-community/compass 2018-12-04 每月 0.9 //www.ayxapp78.com/utility/global-operations/asia/india 2018-12-04 每月 0.9 //www.ayxapp78.com/news-and-press/company-statements/gilead-2017-year-in-review 2018-12-04 每月 0.9 //www.ayxapp78.com/privacy-statements 2018-12-04 每月 0.9 //www.ayxapp78.com/utility/global-operations/europe/france 2018-12-04 每月 0.9 //www.ayxapp78.com/eu-data-disclosure 2018-12-04 每月 0.9 //www.ayxapp78.com/purpose/mission-and-core-values 2018-12-04 每月 0.9 //www.ayxapp78.com/news-and-press/company-statements/grants-for-sclan 2018-12-04 每月 0.9 //www.ayxapp78.com/utility/global-operations/asia/singapore 2018-12-04 每月 0.9 //www.ayxapp78.com/news-and-press/company-statements/harnessing-the-immune-system 2018-12-04 每月 0.9 //www.ayxapp78.com/utility/contact/information-for-suppliers 2018-12-04 每月 0.9 //www.ayxapp78.com/utility/global-operations/south-america/brazil 2018-12-04 每月 0.9 //www.ayxapp78.com/purpose/partnerships-and-community/hiv-age-positively 2018-12-04 每月 0.9 //www.ayxapp78.com/science-and-medicine/research/investigator-sponsored-research 2018-12-04 每月 0.9 //www.ayxapp78.com/news-and-press/company-statements/gilead-2016-year-in-review 2018-12-04 每月 0.9 //www.ayxapp78.com/utility/global-operations/europe/portugal 2018-12-04 每月 0.9 //www.ayxapp78.com/about/ethics-and-code-of-conduct/consumer-product-safety 2018-12-04 每月 0.9 //www.ayxapp78.com/utility/global-operations/asia/taiwan 2018-12-04 每月 0.9 //www.ayxapp78.com/utility/global-operations/europe/netherlands 2018-12-04 每月 0.9 //www.ayxapp78.com/terms-of-use 2018-12-04 每月 0.9 //www.ayxapp78.com/privacy-statements/website-privacy-statement 2018-12-04 每月 0.9 //www.ayxapp78.com/about/ethics-and-code-of-conduct/anti-counterfeiting 2018-12-04 每月 0.9 //www.ayxapp78.com/utility/global-operations/europe/austria 2018-12-04 每月 0.9 //www.ayxapp78.com/utility/global-operations/europe/united-kingdom 2018-12-04 每月 0.9 //www.ayxapp78.com/utility/global-operations/north-america/canada 2018-12-04 每月 0.9 //www.ayxapp78.com/purpose/medication-access/disaster-product-replacement 2018-12-04 每月 0.9 //www.ayxapp78.com/utility/contact 2018-12-04 每月 0.9 //www.ayxapp78.com/purpose/giving/grant-funding 2018-12-04 每月 0.9 //www.ayxapp78.com/news-and-press/company-statements/emergency-disaster-response 2018-12-04 每月 0.9 //www.ayxapp78.com/about/ethics-and-code-of-conduct 2018-12-04 每月 0.9 //www.ayxapp78.com/utility/global-operations/europe/ireland 2018-12-04 每月 0.9 //www.ayxapp78.com/utility/global-operations/north-america/mexico 2018-12-04 每月 0.9 //www.ayxapp78.com/utility/global-operations/europe/denmark 2018-12-04 每月 0.9 //www.ayxapp78.com/purpose/medication-access/global-access 2018-12-04 每月 0.9 //www.ayxapp78.com/news-and-press/press-room 2018-12-04 每月 0.9 //www.ayxapp78.com/science-and-medicine/research/clinical-trials 2018-12-04 每月 0.9 //www.ayxapp78.com/news-and-press/company-statements/corporate-responsibility-report-2015 2018-12-04 每月 0.9 //www.ayxapp78.com/news-and-press/press-room/press-releases/2018/11/gilead-announces-positive-phase-2-results-for-gs9674-in-primary-sclerosing-cholangitis-psc-at-the-liver-meeting-2018 2018-12-04 每月 0.9 //www.ayxapp78.com/news-and-press/company-statements/discount-for-ambisome 2018-12-04 每月 0.9 //www.ayxapp78.com/science-and-medicine/research/compassionate-use 2018-12-04 每月 0.9 //www.ayxapp78.com/utility/global-operations/europe/sweden 2018-12-04 每月 0.9 //www.ayxapp78.com/utility/global-operations/middle-east/united-arab-emirates 2018-12-04 每月 0.9 //www.ayxapp78.com/news-and-press/company-statements/celebrating-transgender-awareness-week 2018-12-04 每月 0.9 //www.ayxapp78.com/utility/global-operations/europe/czech-republic 2018-12-04 每月 0.9 //www.ayxapp78.com/news-and-press/press-room/press-releases/2018/4/gilead-sciences-to-release-first-quarter-2018-financial-results-on-tuesday-may-1-2018 2018-12-04 每月 0.8 //www.ayxapp78.com/news-and-press/press-room/press-releases/2018/9/gilead-sciences-and-precision-biosciences-announce-collaboration-to-develop-therapies-against-hepatitis-b-virus-using-arcus-genome-editing 2018-12-04 每月 0.8 //www.ayxapp78.com/news-and-press/press-room/press-releases/2018/2/kite-a-gilead-company-and-sangamo-therapeutics-announce-collaboration-to-develop-nextgeneration-engineered-cell-therapies-for-the-treatment-of-cancer 2018-12-04 每月 0.8 //www.ayxapp78.com/utility/global-operations/europe/sweden/historical-support 2018-12-04 每月 0.8 //www.ayxapp78.com/about/us-locations?scrollTo=FosterCity 2018-12-04 每月 0.8 //www.ayxapp78.com/news-and-press/press-room/press-releases/2018/5/china-drug-administration-approves-epclusa-sofosbuvirvelpatasvir-gileads-pangenotypic-treatment-for-chronic-hepatitis-c-virus-infection 2018-12-04 每月 0.8 //www.ayxapp78.com/news-and-press/press-room/press-releases/2018/10/phase-3-data-on-filgotinib-in-biologic-experienced-rheumatoid-arthritis-to-be-presented-at-2018-acrarhp-annual-meeting 2018-12-04 每月 0.8 //www.ayxapp78.com/news-and-press/press-room/press-releases/2018/11/gilead-sciences-to-present-at-the-evercore-isi-healthconx-conference-on-tuesday-november-27 2018-12-04 每月 0.8 //www.ayxapp78.com/about/leadership/board-of-directors/jacqueline-barton 2018-12-04 每月 0.8 //www.ayxapp78.com/about/leadership/board-of-directors/john-martin 2018-12-04 每月 0.8 //www.ayxapp78.com/news-and-press/press-room/press-releases/2018/2/jacqueline-k-barton-phd-joins-gilead-sciences-board-of-directors 2018-12-04 每月 0.8 //www.ayxapp78.com/news-and-press/press-room/press-releases/2018/3/gilead-sciences-norbert-bischofberger-phd-to-step-down-john-mchutchison-md-appointed-chief-scientific-officer-and-andrew-cheng-md-phd-appointed-chief-medical-officer 2018-12-04 每月 0.8 //www.ayxapp78.com/purpose/medication-access/global-access/visceral-leishmaniasis 2018-12-04 每月 0.8 //www.ayxapp78.com/purpose/giving/grant-funding/apply-latin-america-and-caribbean 2018-12-04 每月 0.8 //www.ayxapp78.com/about/leadership/senior-management/taiyin-yang 2018-12-04 每月 0.8 //www.ayxapp78.com/utility/global-operations/europe/netherlands/historical-grants-netherlands 2018-12-04 每月 0.8 //www.ayxapp78.com/About/US-Locations 2018-12-04 每月 0.8 //www.ayxapp78.com/utility/global-operations/europe/poland/historical-support 2018-12-04 每月 0.8 //www.ayxapp78.com/utility/global-operations/europe/netherlands/dutch-translation 2018-12-04 每月 0.8 //www.ayxapp78.com/utility/global-operations/europe/switzerland/french-translation 2018-12-04 每月 0.8 //www.ayxapp78.com/news-and-press/press-room/press-releases/2018/2/gilead-sciences-announces-senior-management-change 2018-12-04 每月 0.8 //www.ayxapp78.com/news-and-press/press-room/press-releases/2018/8/china-national-drug-administration-approves-gileads-genvoya-elvitegravir-cobicistat-emtricitabine-and-tenofovir-alafenamide-a-single-tablet-regimen-for-the-treatment-of-hiv1-infection 2018-12-04 每月 0.8 //www.ayxapp78.com/about/leadership/board-of-directors/kelly-kramer 2018-12-04 每月 0.8 //www.ayxapp78.com/utility/global-operations/europe/switzerland/dutch-translation 2018-12-04 每月 0.8 //www.ayxapp78.com/utility/global-operations/europe/germany/historical-support 2018-12-04 每月 0.8 //www.ayxapp78.com/utility/global-operations/europe/portugal/portugal-translation 2018-12-04 每月 0.8 //www.ayxapp78.com/news-and-press/press-room/press-releases/2018/4/european-chmp-adopts-positive-opinion-for-gileads-biktarvy-bictegravir-emtricitabine-tenofovir-alafenamide 2018-12-04 每月 0.8 //www.ayxapp78.com/purpose/giving/grant-funding/faqs-outside-north-america 2018-12-04 每月 0.8 //www.ayxapp78.com/about/us-locations?scrollTo=SeatleWA 2018-12-04 每月 0.8 //www.ayxapp78.com/news-and-press/press-room/press-releases/2018/7/kite-and-gadeta-announce-strategic-collaboration-to-advance-gamma-delta-t-cell-receptor-technology-for-solid-tumors 2018-12-04 每月 0.8 //www.ayxapp78.com/utility/global-operations/europe/belgium-luxembourg/dutch-translation 2018-12-04 每月 0.8 //www.ayxapp78.com/news-and-press/press-room/press-releases/2018/6/kite-announces-initial-results-from-a-phase-1-study-of-t-cell-receptor-tcr-cell-therapy-in-hpv16positive-solid-tumors 2018-12-04 每月 0.8 //www.ayxapp78.com/news-and-press/press-room/press-releases/2018/11/gilead-to-present-latest-scientific-research-in-hematologic-malignancies-and-solid-tumors-at-ash-2018 2018-12-04 每月 0.8 //www.ayxapp78.com/news-and-press/press-room/press-releases/2018/11/gilead-presents-data-from-nonalcoholic-steatohepatitis-nash-development-program-for-advanced-fibrosis-at-the-liver-meeting-2018 2018-12-04 每月 0.8 //www.ayxapp78.com/news-and-press/press-room/press-releases/2018/8/gilead-sciences-announces-executive-promotions 2018-12-04 每月 0.8 //www.ayxapp78.com/utility/global-operations/europe/belgium-luxembourg/historical-support 2018-12-04 每月 0.8 //www.ayxapp78.com/news-and-press/press-room/press-releases/2018/7/gilead-sciences-announces-second-quarter-2018-financial-results 2018-12-04 每月 0.8 //www.ayxapp78.com/utility/global-operations/north-america/canada/divulgation-volontair-des-paiments 2018-12-04 每月 0.8 //www.ayxapp78.com/news-and-press/press-room/press-releases/2018/7/gilead-sciences-announces-third-quarter-2018-dividend 2018-12-04 每月 0.8 //www.ayxapp78.com/news-and-press/press-room/press-releases/2018/5/harish-manwani-joins-gilead-sciences-board-of-directors 2018-12-04 每月 0.8 //www.ayxapp78.com/purpose/giving/grant-funding/apply-asia 2018-12-04 每月 0.8 //www.ayxapp78.com/news-and-press/press-room/press-releases/2018/2/gilead-sciences-announces-10-percent-increase-in-first-quarter-2018-dividend 2018-12-04 每月 0.8 //www.ayxapp78.com/about/leadership/senior-management/alessandro-riva 2018-12-04 每月 0.8 //www.ayxapp78.com/news-and-press/press-room/press-releases/2018/10/gilead-sciences-announces-fourth-quarter-2018-dividend 2018-12-04 每月 0.8 //www.ayxapp78.com/news-and-press/press-room/press-releases/2018/5/gilead-sciences-to-present-at-the-bank-of-america-merrill-lynch-healthcare-conference-on-wednesday-may-16 2018-12-04 每月 0.8 //www.ayxapp78.com/news-and-press/press-room/press-releases/2018/10/gilead-sciences-to-release-third-quarter-2018-financial-results-on-thursday-october-25-2018 2018-12-04 每月 0.8 //www.ayxapp78.com/news-and-press/press-room/press-releases/2018/9/gilead-and-galapagos-announce-filgotinib-meets-primary-and-all-key-secondary-endpoints-in-first-phase-3-study-in-rheumatoid-arthritis 2018-12-04 每月 0.8 //www.ayxapp78.com/about/leadership/senior-management/gregg-alton 2018-12-04 每月 0.8 //www.ayxapp78.com/utility/global-operations/europe/czech-republic/historical-support 2018-12-04 每月 0.8 //www.ayxapp78.com/purpose/giving/grant-funding/apply-australia 2018-12-04 每月 0.8 //www.ayxapp78.com/utility/global-operations/europe/germany/german-translation 2018-12-04 每月 0.8 //www.ayxapp78.com/purpose/medication-access/global-access/hiv-aids 2018-12-04 每月 0.8 //www.ayxapp78.com/news-and-press/press-room/press-releases/2018/10/positive-trial-results-with-filgotinib-in-psoriatic-arthritis-and-ankylosing-spondylitis-both-published-in-the-lancet 2018-12-04 每月 0.8 //www.ayxapp78.com/utility/global-operations/europe/turkey/turkish-translation 2018-12-04 每月 0.8 //www.ayxapp78.com/news-and-press/press-room/press-releases/2018/6/european-chmp-adopts-positive-opinion-for-yescarta-axicabtagene-ciloleucel-for-the-treatment-of-relapsed-or-refractory-dlbcl-and-pmbcl-after-two-or-more-lines-of-systemic-therapy 2018-12-04 每月 0.8 //www.ayxapp78.com/utility/global-operations/europe/italy/italian-translation 2018-12-04 每月 0.8 //www.ayxapp78.com/about/leadership/board-of-directors/john-milligan 2018-12-04 每月 0.8 //www.ayxapp78.com/news-and-press/press-room/press-releases/2018/5/gilead-sciences-announces-second-quarter-2018-dividend 2018-12-04 每月 0.8 //www.ayxapp78.com/utility/global-operations/europe/france/transparency 2018-12-04 每月 0.8 //www.ayxapp78.com/purpose/giving/asia-rainbow-grant 2018-12-04 每月 0.8 //www.ayxapp78.com/utility/global-operations/europe/poland/polish-translation 2018-12-04 每月 0.8 //www.ayxapp78.com/utility/global-operations/australia/australia-new-zealand/australia-privacy 2018-12-04 每月 0.8 //www.ayxapp78.com/utility/global-operations/north-america/canada/voluntary-disclosure-of-payments 2018-12-04 每月 0.8 //www.ayxapp78.com/news-and-press/press-room/press-releases/2018/8/gilead-sciences-appoints-laura-hamill-as-executive-vice-president-worldwide-commercial-operations 2018-12-04 每月 0.8 //www.ayxapp78.com/news-and-press/press-room/press-releases/2018/10/kite-and-hifibio-therapeutics-announce-a-research-collaboration-to-develop-technology-for-the-potential-discovery-of-neoantigenreactive-t-cell-receptors-tcrs-for-the-treatment-of-cancer 2018-12-04 每月 0.8 //www.ayxapp78.com/news-and-press/press-room/press-releases/2018/2/us-food-and-drug-administration-approves-gileads-biktarvy-bictegravir-emtricitabine-tenofovir-alafenamide-for-treatment-of-hiv1-infection 2018-12-04 每月 0.8 //www.ayxapp78.com/news-and-press/press-room/press-releases/2018/11/gilead-presents-latest-data-from-viral-hepatitis-research-programs-at-the-liver-meeting-2018 2018-12-04 每月 0.8 //www.ayxapp78.com/news-and-press/press-room/press-releases/2018/10/gilead-sciences-announces-third-quarter-2018-financial-results 2018-12-04 每月 0.8 //www.ayxapp78.com/news-and-press/press-room/press-releases/2018/10/gilead-sciences-and-tango-therapeutics-announce-strategic-collaboration-to-develop-next-generation-targeted-immuno-oncology-therapies 2018-12-04 每月 0.8 //www.ayxapp78.com/about/leadership/senior-management/andrew-dickinson 2018-12-04 每月 0.8 //www.ayxapp78.com/about/leadership/board-of-directors/george-shultz 2018-12-04 每月 0.8 //www.ayxapp78.com/utility/global-operations/europe/austria/historical-support 2018-12-04 每月 0.8 //www.ayxapp78.com/news-and-press/press-room/press-releases/2018/7/gilead-announces-new-data-on-the-impact-of-truvada-emtricitabine-and-tenofovir-disoproxil-fumarate-for-preexposure-prophylaxis-prep-on-the-number-of-hiv-diagnoses-in-the-united-states 2018-12-04 每月 0.8 //www.ayxapp78.com/news-and-press/press-room/press-releases/2018/6/gilead-sciences-announces-leadership-changes-in-corporate-development-and-strategy 2018-12-04 每月 0.8 //www.ayxapp78.com/utility/global-operations/europe/belgium-luxembourg/french-translation 2018-12-04 每月 0.8 //www.ayxapp78.com/news-and-press/press-room/press-releases/2018/6/european-commission-grants-marketing-authorization-for-gileads-biktarvy-bictegravir-emtricitabine-tenofovir-alafenamide-for-the-treatment-of-hiv1-infection 2018-12-04 每月 0.8 //www.ayxapp78.com/news-and-press/press-room/press-releases/2018/6/gilead-sciences-chief-scientific-officer-john-mchutchison-appointed-officer-of-the-order-of-australia 2018-12-04 每月 0.8 //www.ayxapp78.com/utility/global-operations/europe/italy/historical-support 2018-12-04 每月 0.8 //www.ayxapp78.com/news-and-press/press-room/press-releases/2018/10/gilead-to-present-wide-ranging-new-data-on-treatment-and-diagnosis-of-liver-diseases-at-the-liver-meeting-2018 2018-12-04 每月 0.8 //www.ayxapp78.com/purpose/giving/grant-funding/apply-europe 2018-12-04 每月 0.8 //www.ayxapp78.com/news-and-press/press-room/press-releases/2018/5/gilead-sciences-to-present-at-the-goldman-sachs-39th-annual-global-healthcare-conference-on-wednesday-june-13 2018-12-04 每月 0.8 //www.ayxapp78.com/news-and-press/press-room/press-releases/2018/6/hookipa-and-gilead-enter-into-a-collaboration-and-license-agreement-to-develop-immunotherapies-against-hiv-and-hepatitis-b 2018-12-04 每月 0.8 //www.ayxapp78.com/news-and-press/press-room/press-releases/2018/3/gilead-presents-results-from-phase-3-study-evaluating-patients-who-switched-to-biktarvy-bictegravir-emtricitabine-and-tenofovir-alafenamide-from-regimen-containing-abacavir-dolutegravir-and-lamivudine 2018-12-04 每月 0.8 //www.ayxapp78.com/news-and-press/press-room/press-releases/2018/1/kite-announces-clinical-collaboration-to-evaluate-investigational-combination-of-yescarta-axicabtagene-ciloleucel-and-pfizers-utomilumab-in-large-bcell-lymphoma 2018-12-04 每月 0.8 //www.ayxapp78.com/news-and-press/press-room/press-releases/2018/7/michael-amoroso-to-join-kite-as-senior-vice-president-and-head-of-worldwide-commercial-cell-therapy 2018-12-04 每月 0.8 //www.ayxapp78.com/purpose/giving/grant-funding/terms-and-conditions-outside-north-america 2018-12-04 每月 0.8 //www.ayxapp78.com/utility/global-operations/australia/australia-new-zealand/australia-transparency 2018-12-04 每月 0.8 //www.ayxapp78.com/utility/global-operations/europe/united-kingdom/historical-support 2018-12-04 每月 0.8 //www.ayxapp78.com/utility/global-operations/south-america/brazil/portuguese-translation 2018-12-04 每月 0.8 //www.ayxapp78.com/utility/global-operations/europe/austria/german-translation 2018-12-04 每月 0.8 //www.ayxapp78.com/purpose/giving/grant-funding/apply-north-america 2018-12-04 每月 0.8 //www.ayxapp78.com/purpose/medication-access/global-access/access-partnerships 2018-12-04 每月 0.8 //www.ayxapp78.com/about/leadership/board-of-directors/richard-whitely 2018-12-04 每月 0.8 //www.ayxapp78.com/utility/global-operations/europe/switzerland/historical-support 2018-12-04 每月 0.8 //www.ayxapp78.com/news-and-press/press-room/press-releases/2018/1/gilead-sciences-to-release-fourth-quarter-and-full-year-2017-financial-results-on-tuesday-february-6-2018 2018-12-04 每月 0.8 //www.ayxapp78.com/about/leadership/board-of-directors/harish-manwani 2018-12-04 每月 0.8 //www.ayxapp78.com/about/leadership/senior-management/john-milligan 2018-12-04 每月 0.8 //www.ayxapp78.com/utility/global-operations/europe/france/charitable-organizations 2018-12-04 每月 0.8 //www.ayxapp78.com/news-and-press/press-room/press-releases/2018/3/gilead-announces-data-from-new-preclinical-study-evaluating-a-combination-of-an-investigational-tlr7-agonist-and-an-investigational-hiv-envelope-targeting-antibody-in-shivinfected-virally-suppressed-monkeys 2018-12-04 每月 0.8 //www.ayxapp78.com/utility/global-operations/europe/spain/historical-support 2018-12-04 每月 0.8 //www.ayxapp78.com/news-and-press/press-room/press-releases/2018/5/kite-announces-new-worldwide-facilities-and-expanded-collaboration-with-national-cancer-institute-to-support-cell-therapy-pipeline 2018-12-04 每月 0.8 //www.ayxapp78.com/purpose/giving/grant-funding/faqs-north-america 2018-12-04 每月 0.8 //www.ayxapp78.com/utility/global-operations/europe/denmark/historical-support 2018-12-04 每月 0.8 //www.ayxapp78.com/utility/search 2018-12-04 每月 0.8 //www.ayxapp78.com/about/leadership/senior-management/brett-pletcher 2018-12-04 每月 0.8 //www.ayxapp78.com/news-and-press/press-room/press-releases/2018/5/us-food-and-drug-administration-approves-expanded-indication-for-truvada-emtricitabine-and-tenofovir-disoproxil-fumarate-for-reducing-the-risk-of-acquiring-hiv1-in-adolescents 2018-12-04 每月 0.8 //www.ayxapp78.com/news-and-press/press-room/press-releases/2018/9/gilead-subsidiary-to-launch-authorized-generics-of-epclusa-sofosbuvirvelpatasvir-and-harvoni-ledipasvirsofosbuvir-for-the-treatment-of-chronic-hepatitis-c 2018-12-04 每月 0.8 //www.ayxapp78.com/about/leadership/senior-management/robin-washington 2018-12-04 每月 0.8 //www.ayxapp78.com/news-and-press/press-room/press-releases/2018/9/gilead-and-galapagos-announce-tortuga-phase-2-study-of-filgotinib-in-ankylosing-spondylitis-achieves-primary-endpoint 2018-12-04 每月 0.8 //www.ayxapp78.com/about/leadership/senior-management/william-lee 2018-12-04 每月 0.8 //www.ayxapp78.com/news-and-press/press-room/press-releases/2018/7/gilead-sciences-to-release-second-quarter-2018-financial-results-on-wednesday-july-25-2018 2018-12-04 每月 0.8 //www.ayxapp78.com/about/leadership/senior-management/laura-hamill 2018-12-04 每月 0.8 //www.ayxapp78.com/news-and-press/press-room/press-releases/2018/2/gilead-sciences-announces-fourth-quarter-and-full-year-2017-financial-results 2018-12-04 每月 0.8 //www.ayxapp78.com/news-and-press/press-room/press-releases/2018/8/yescarta-axicabtagene-ciloleucel-receives-european-marketing-authorization-for-the-treatment-of-relapsed-or-refractory-dlbcl-and-pmbcl-after-two-or-more-lines-of-systemic-therapy 2018-12-04 每月 0.8 //www.ayxapp78.com/news-and-press/press-room/press-releases/2018/10/gilead-announces-96week-results-from-phase-3-study-of-biktarvy-bictegravir-emtricitabine-tenofovir-alafenamide-for-the-treatment-of-hiv1-in-adults-new-to-hiv-therapy 2018-12-04 每月 0.8 //www.ayxapp78.com/news-and-press/press-room/press-releases/2018/5/gilead-and-galapagos-announce-results-with-filgotinib-in-the-phase-2-equator-study-in-psoriatic-arthritis-and-progression-into-phase-3-for-the-selection-study-in-ulcerative-colitis 2018-12-04 每月 0.8 //www.ayxapp78.com/utility/global-operations/europe/norway/historical-support 2018-12-04 每月 0.8 //www.ayxapp78.com/utility/global-operations/europe/portugal/historical-support 2018-12-04 每月 0.8 //www.ayxapp78.com/utility/global-operations/europe/spain/spanish-translation 2018-12-04 每月 0.8 //www.ayxapp78.com/news-and-press/press-room/press-releases/2018/4/gilead-and-verily-announce-scientific-collaboration-to-identify-and-understand-immunological-and-molecular-drivers-of-inflammatory-diseases 2018-12-04 每月 0.8 //www.ayxapp78.com/about/us-locations?scrollTo=Fremont 2018-12-04 每月 0.8 //www.ayxapp78.com/about/leadership/senior-management/katie-watson 2018-12-04 每月 0.8 //www.ayxapp78.com/utility/global-operations/europe/greece/greek 2018-12-04 每月 0.8 //www.ayxapp78.com/about/leadership/board-of-directors/per-wold-olsen 2018-12-04 每月 0.8 //www.ayxapp78.com/news-and-press/press-room/press-releases/2018/6/kite-announces-new-data-analyses-for-car-t-therapy-in-patients-with-blood-cancers-at-the-2018-american-society-of-clinical-oncology-meeting 2018-12-04 每月 0.8 //www.ayxapp78.com/about/leadership/board-of-directors/john-cogan 2018-12-04 每月 0.8 //www.ayxapp78.com/utility/global-operations/europe/greece/historical-support 2018-12-04 每月 0.8 //www.ayxapp78.com/utility/global-operations/europe/finland/historical-support 2018-12-04 每月 0.8 //www.ayxapp78.com/purpose/giving/grant-funding/apply-africa 2018-12-04 每月 0.8 //www.ayxapp78.com/news-and-press/press-room/press-releases/2018/7/gilead-sciences-announces-ceo-john-f-milligan-to-step-down 2018-12-04 每月 0.8 //www.ayxapp78.com/about/leadership/senior-management/john-mchutchinson 2018-12-04 每月 0.8 //www.ayxapp78.com/purpose/medication-access/global-access/viral-hepatitis 2018-12-04 每月 0.8 //www.ayxapp78.com/about/leadership/board-of-directors/kevin-lofton 2018-12-04 每月 0.8 //www.ayxapp78.com/about/leadership/board-of-directors/gayle-edlund-wilson 2018-12-04 每月 0.8 //www.ayxapp78.com/news-and-press/press-room/press-releases/2018/8/gilead-sciences-to-present-at-the-morgan-stanley-global-healthcare-conference-on-wednesday-september-12 2018-12-04 每月 0.8 //www.ayxapp78.com/news-and-press/press-room/press-releases/2018/4/gilead-presents-data-on-multiple-investigational-regimens-for-the-treatment-of-patients-with-nonalcoholic-steatohepatitis-nash-and-advanced-fibrosis-at-the-international-liver-congress-2018 2018-12-04 每月 0.8 //www.ayxapp78.com/news-and-press/press-room/press-releases/2018/2/gilead-sciences-to-present-at-the-rbc-capital-markets-2018-global-healthcare-conference-on-wednesday-february-21 2018-12-04 每月 0.8 //www.ayxapp78.com/purpose/giving/grant-funding/terms-and-conditions-north-america 2018-12-04 每月 0.8 //www.ayxapp78.com/news-and-press/press-room/press-releases/2018/5/gilead-sciences-announces-first-quarter-2018-financial-results 2018-12-04 每月 0.8 //www.ayxapp78.com/about/us-locations?scrollTo=Oceanside 2018-12-04 每月 0.8 //www.ayxapp78.com/news-and-press/press-room/press-releases/2018/5/gilead-sciences-to-present-at-the-jefferies-2018-healthcare-conference-on-wednesday-june-6 2018-12-04 每月 0.8 //www.ayxapp78.com/utility/global-operations/europe/turkey/historical-support 2018-12-04 每月 0.8 //www.ayxapp78.com/about/us-locations?scrollTo=SanDimas 2018-12-04 每月 0.8 //www.ayxapp78.com/utility/global-operations/europe/france/french-translation 2018-12-04 每月 0.8 //www.ayxapp78.com/news-and-press/press-room/press-releases/2018/9/gilead-enters-licensing-agreement-with-trianni-for-use-of-trianni-transgenic-human-monoclonal-antibody-discovery-platform 2018-12-04 每月 0.8 //www.ayxapp78.com/utility/global-operations/europe/belgium-luxembourg/historical-support/french-translation 2018-12-04 每月 0.7 //www.ayxapp78.com/500.html?aspxerrorpath=/news-and-press/press-room/press-releases/2018/3/gilead-presents-data-from-phase-3-study-evaluating-women-who-switched-to-biktarvy-bictegravir-emtricitabine-and-tenofovir-alafenamide-from-a-boosted-protease-inhibitorbased-regimen-or-boosted-elvitegravircontaining-regimen 2018-10-18 每月 0.7 //www.ayxapp78.com/utility/global-operations/europe/france/charitable-organizations/french-translation 2018-12-04 每月 0.7 //www.ayxapp78.com/utility/global-operations/europe/portugal/historical-support/portuguese-translation 2018-12-04 每月 0.7 //www.ayxapp78.com/utility/global-operations/europe/france/mentions-legales 2018-12-04 每月 0.7 //www.ayxapp78.com/utility/global-operations/europe/france/historical-support 2018-12-04 每月 0.7 //www.ayxapp78.com/utility/global-operations/europe/belgium-luxembourg/historical-support/dutch-translation 2018-12-04 每月 0.7 //www.ayxapp78.com/500.html?aspxerrorpath=/404.aspx 2018-10-18 每月 0.6